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Last year, the European Archives of Psychiatry and Clin-
ical Neurosciences have published nearly 80 articles. This
editorial wants to summarize those articles of 2009 which
have been cited most frequently and/or seem to be of some
interest to the readers. Therefore, the selection of the
articles is subjective and includes articles being of some
interest to the reader or having been well cited already
shortly after publishing.
Therapies
Recently, there has been some debate to what extent anti-
depressants seem to work. Therefore, it is interesting and
important to have meta-analyses reviewing this issue. The
paper of Bauer et al. [1] reviewed the effect of venlafaxine
compared to other antidepressants and placebo in the
treatment of major depression. In a meta-analysis they used
all available trials of venlafaxin in the treatment of major
depressive disorders including treatment-resistant depres-
sion and long-term relapse prevention. Trials were identi-
ﬁed trough searches of Medline, Embase, Cochrane Library
and trough assessing unpublished trials held by the man-
ufacturer. Compared to all SSRIs venlafaxine was associ-
ated with a greater response (odds ratio 1.15) and remission
(odds ratio 1.19). Compared to tricyclics, response to
venlafaxine was not statistically signiﬁcantly different
using a full random effects method with an odds ratio of
1.22. Therefore, the meta-analysis provides evidence of the
clinical efﬁcacy of venlafaxine in achieving therapeutic
response in remission in patients with major depression. It
is more effective than SSRIs and at least as effective as
tricyclics antidepressants but better tolerated. In addition, it
seemed to be effective in reducing relapse when given long
term after major depressive episodes.
This meta-analysis stresses the safe and well tolerated
use of a more recent dual-acting substance in the treatment
of major depression.
Remaining with severe forms of depression there are
two articles dealing with the subject of deep brain stimu-
lation, one by Juckel et al. [2] reviewing the literature on
psychosurgery and deep brain stimulation as an ultima ratio
treatment option in refractory depression. Covering the
aspect of ethics, the second article by Kuhn et al. [3]
summarizes the difﬁcult history of psychosurgery in psy-
chiatric illnesses and critically discusses pros and cons of
deep brain stimulation. This is especially rolled out on the
background of the question how ethical it is to suggest deep
brain stimulation to a severely psychiatric ill patient.
Proper diagnosis and expert neurosurgical knowledge are
two important factors in this context.
With respect to depression an article needs to be men-
tioned ﬁnally dealing with the stigma of psychiatric treat-
ment and help-seeking intentions in depressive disorders. In
a large-scale representative population survey Schomerus
et al. [4] found contrary to expectations, anticipated dis-
crimination from others was unrelated to help-seeking
intentions, while personal discriminatory attitudes seem to
hinder help-seeking. This is most interesting to note as the
survey comprised not only probands from the general pop-
ulation but also persons with current depressive syndromes.
If these ﬁndings hold up, future anti-stigma campaigns need
to improve self-stigmatization to the same extent as they are
trying to reduce anticipated discrimination currently.
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dementia. There is an interesting article by Mendes et al.
[5] demonstrating that lithium reduces Gsk3b mRNA levels
in primary cultures of rat cortical and hippocampal neurons
as well as peripheral leukocytes of adult rats treated with
lithium in addition. As there is evidence of increased sys-
temic expression of active Gsk3b in Alzheimer’s disease
patients being associated with the formation of senile pla-
ques and neuroﬁbrillary tangles, this might be an interest-
ing promising target for further interventions. It is needless
to say, that lithium is one promising neuroprotective sub-
stance showing an effect in restoring neuroplasticity in
depression and other psychiatric disorders, so far.
Beside the potential impact of lithium on the progression
in dementia, cholinesterase inhibitors are part of the state-
of-the-art treatment regime. However, recently it has been
under intense debate to what extent they are beneﬁcial for
subjects with Alzheimer’s disease. In a recent meta-anal-
ysis Diniz et al. [6] found that the relative risk for pro-
gression from MCI to Alzheimer’s disease/dementia is
signiﬁcantly reduced in the cholinesterase-treated com-
pared to the placebo-treated group. The patients on the
ChEI group had a signiﬁcantly higher all-cause dropout
risk but showed no signiﬁcantly different relative risk for
serious adverse events. Therefore, in summary, this meta-
analysis demonstrates that the long-term use of ChEI in
subjects with MCI may attenuate the risk of progression to
AD/dementia.
One of the most controversial suggestions of current
guidelines on treatment of schizophrenia is to stick to
monotherapy. Contrary to this suggestion there is good
evidence demonstrating 30–50% of all patients with
schizophrenia are treated with more than one neuroleptic.
One argument against polypharmacy is the increase of side
effects. In a well controlled large-scale study Correll et al.
[7] could show that polytherapy and monotherapy patients
were similar with regard to QTc duration, QTc dispersion
and proportion of patients with gender-adjusted QTc pro-
longation. The QTc duration had only a modest correlation
with the total antipsychotic dose. The authors conclude the
common practice of polytherapy with two atypical anti-
psychotics does not seem to lead to a signiﬁcant QTc
prolongation compared to monotherapy.
Etiology and pathogenesis
Looking at the molecular etiology of psychiatric illnesses
especially psychoses, the genome-wide association studies
(GWAS) are heading the discussion. Despite this, there is
substantial work in progress to understand the function of
important risk gene like NRG-1. In an interesting paper
Kircher et al. [8] found correlates of the relevant ICE SNP
of the NRG-1 in ﬁrst episodes of schizophrenia with
cerebral activation in fronto-temporal regions.
Using a prominent phenotype for the search of new risk
genes Kishi et al. [9] looked for the association of
the Clock gene, schizophrenia and mood disorders in the
Japanese population. Although the disregulation of the
circadian rhythms as well as the dopamine metabolism are
central to this disorders, low association with the Clock
gene was found, which was centrally involved in circadian
rhythmicity.
Beside the genomic approach the analyses of the pro-
teome seem to be another promising ﬁeld of trying to ﬁnd
key players in the pathophysiology of psychiatric disorders.
Using shotgun proteome analysis Martins-de-Souza et al.
[10] analyzed postmortem tissue of schizophrenic patients.
The analysis resulted in the identiﬁcation of 1,261 proteins
of which 84 showed statistically signiﬁcant differential
expression. Of those candidates involved in the immune
system, calcium homeostasis, cytoskeleton assembly and
energy metabolism seem to be of special interest.
Finally, looking at the context of etiology and patho-
genesis gene–environment interaction seems to be of cen-
tral interest currently. One of the key environmental factors
being involved in the pathogenesis of psychotic illness
seems to be cannabis. Therefore, an interesting overview of
Lutz [11], one of the leading experts in this ﬁeld, should be
quoted here as well.
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